Helicobacter pylori-associated peptic ulcer disease

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 2, 1997, Pages 273-282

  Bodger, K ^a   Daly, M J ^a   Heatley, R V ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; TINIDAZOLE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMICS; ENDOSCOPY; GASTRODUODENAL ULCER; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; HELICOBACTER INFECTION; MICROBIOLOGY;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 0031113917     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.145321000.x     Document Type: Review

References (52)

1. Peterson WL. Current concepts: Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324: 1043-8.
2. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52.
3. NIH consensus conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 994; 272: 65-9.
4. Kurata JH, Haile BM. Epidemiology of peptic ulcer disease. Clin Gastroenterol 1984; 13: 289-305.
5. Kurata JH, Nogowa AN, Abbey DE, Petersen F. A prospective study of the risk for peptic ulcer disease in Seventh-Day Adventists. Gastroenterology 1992; 102: 902-9.
6. Bonnevie O. The incidence of gastric ulcer in Copenhagen County. Scand J Gastroenterol 1975; 10: 231-9.
7. Bonnevie O. The incidence of duodenal ulcer in Copenhagen County. Scand J Gastroenterol 1975; 10: 385-93.
8. Kurata JH. Ulcer epidemiology: an overview and proposed research framework. Gastroenterology 1989; 96(Suppl. 2): 569-80.
9. Lancaster Smith M, Gough K, Wells N, Miocevich M. An economic analysis of ranitidine vs. cimetidine in the prevention of duodenal ulcer recurrence. Br J Med Econ 1992; 2: 25-36.
10. Tilvis RS, Vuoristo M, Varis K. Changed profile of peptic ulcer disease in hospital patients during 1969-1984 in Finland. Scand J Gastroenterol 1987; 22: 1238-44.
11. 2-receptor antagonists. Ann Surg 1988; 207: 4-6.
12. Bardhan KD, Cust G, Hinchliffe RFC, et al. Changing pattern of admissions and operations for duodenal ulcer. Br J Surg 1989; 76: 230-6.
13. Office of Population Census and Surveys. Registrar General's Statistical Review, 1980-1990. London: HMSO.
14. 2-antagonist. Aliment Pharmacol Ther 1988; 2: 297-309.
15. Pym B, Sandstad J, Seville P, et al. Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer. Gastroenterology 1990; 99: 27-35.
16. Van Deventer GM, Osterhaus JT. Pharmaco-economic benefits of ranitidine maintenance therapy. A retrospective analysis of a clinical trial. J Clin Res Pharmacoepidemiol 1992; 6: 29-37.
17. Ruszniewski P, Levy E, Mignon M et Groupe D'Etude de la Maladie Ulcéreuse Duodénale (GEMUD). Analyse économique du traitement d'entretien de la maladie ulcéreuse duodénale par la ranitidine 150 mg. Gastroenterol Clin Biol 1992; 16: 842-7.
18. Sonnenberg A. Costs of medical and surgical treatment of duodenal ulcer. Gastroenterology 1989; 96: 1445-52.
19. Ruszniewski P. Coût de la maladie ulcéreuse duodénale en France: une enquête macroéconomique. In: Mignon M, Galmiche JP, Ruszniewski P, Pappo M, eds. Contrôle de la Sécrétion Acide. Paris: JohnLibbey Eurotext, 1988: 293-302.
20. OHE Compendium of Health Statistics, 8th edn. London: Office of Health Economics, 1992.
21. Moore RA. Helicobacter pylori and peptic ulcer: A systematic review of effectiveness and an overview of the economic benefits of implementing what is known to be effective. Oxford: Anglia & Oxford RHA, 1995.
22. Roberts SJ, Bateman DN. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995; 9: 137-43.
23. Ryder SD, O'Reilly S, Miller RJ, et al. Long term acid suppressing treatment in general practice. Br Med J 1994; 308: 827-30.
24. Goudie BM, McKenzie PE, Cipriano J, Griffin EM, Murray FE. Repeat prescribing of ulcer healing drugs in general practice-prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996; 10: 147-50.
25. Collins R, Coghlan JG, O'Morain C. Helicobacter pylori and ulcer treatment. In: Rathbone BJ, Heatley RV, eds. Helicobacter pylori and Gastroduodenal Disease, 2nd edn. London: Blackwell, 1992: 244-58.
26. Thijs JC, Kuipers EJ, van Zwet AA, Pena AS, de Graff J. Treatment of Helicobacter pylori infections. Q J Med 1995; 88: 369-89.
27. Imperiale TF, Speroff T, Cebul R, McCullough AJ. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995; 123: 665-72.
28. O'Brien, Goeree R, Mohamed AH, Hunt R. Cost-effectiveness of H. pylori eradication in the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958-64.
29. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922-8.
30. Unge P, Jönsson B, Stålhammar N-O. The cost-effectiveness of H. pylori eradication vs. maintenance and episodic treatment in duodenal ulcer patients in Sweden. Pharmacoeconomics 1995; 8(5): 410-27.
31. Briggs AH, Sculpher MJ, Logan RPH, et al. Cost-effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. Br Med J 1996; 312: 1321-5.
32. Sonnenberg A. Comparison of different treatment strategies for treatment of duodenal ulcer. Br Med J 1985; 290: 1185-7.
33. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol 1993; 28(Suppl. 196): 34-7.
34. Fendrick AM, Chernew ME, Hirth RA, Bloom B. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995; 123: 260-8.
35. Talley NJ. Non-ulcer dyspepsia: myths and realities. Aliment Pharmacol Ther 1991; 5(Suppl 1): 145-62.
36. Cromwell DM, Pasricha PJ. Endoscopy or empirical treatment for peptic ulcer disease: decisions, decisions... Gastroenterology 1996; 110: 1314-9.
37. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110: 72-83.
38. British Society of Gastroenterology. Guidelines in gastroenterology: Dyspepsia management guidelines. September 1996.
39. Powell KU, Bell GD, Bolton GH, et al. Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications. Quart J Med 1994; 87: 283-90.
40. Labenz J, Tillenburg B, Peitz U, Börsch G. Long-term consequences of Helicobacter pylori eradication: clinical aspects. Scand J Gastroenterol 1996; 31(Suppl. 215): 111-15.
41. Phull PS, Ryder SD, Halliday D, et al. The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease-a community based study. Postgrad Med J 1995; 71: 413-18.
42. Graham DY, Hepps KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of H. pylori reduces the rate of rebleeding in complicated peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-42.
43. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32.
44. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-63.
45. Tytgat GNJ. Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-68.
46. Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996; 31 (Suppl. 215): 74-81.
47. 2-receptor antagonists for Helicobacter pylori eradication-a meta-analysis. Lancet 1996; 347: 763.
48. Pounder RE. The management of Helicobacter pylori infection. Prescribers J 1996; 36: 135-40.
49. Monthly Index of Medical Specialities, Surrey: Galleon Ltd, August 1996.
50. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996; 91(2): 239-45.
51. Phull PS, Halliday D, Price AB, Jacyna MR. Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication. Br Med J 1996; 312: 349-50.
52. Bodger K, Heatley RV. Testing to check success of treatment to eradicate H. pylori-Patients' well being should not be risked for marginal cost savings. Br Med J 1996; 312: 1361-2.